Selinexor

(Xpovio)

Selinexor

Drug updated on 11/14/2023

Dosage FormTablet (oral: 20 mg 40 mg, 50 mg, 60 mg)
Drug ClassNuclear export inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
  • Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
  • Indicated for the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL), not otherwise specified, including DLBC arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Xpovio (selinexor) Prescribing Information.2022Karyopharm Therapeutics Inc., Newton, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines